Special Issue

Use of Antibodies/Antivenom Against Envenoming

Guest Editors:

Prof. Dr. Wayne Hodgson
Monash Venom Group,
Department of Pharmacology,
Monash University, Victoria
3800, Australia
wayne.hodgson@monash.edu

Prof. Dr. Geoff Isbister
Department of Clinical Toxicology and Pharmacology,
Calvary Mater Newcastle,
Newcastle, Australia
geoff.isbister@gmail.com

Deadline for manuscript submissions: 15 April 2017

Message from the Guest Editors

Dear Colleagues,

Antivenoms remain the mainstay treatment of systemic envenoming in humans following bites by a range of animals. However, there is still considerable debate about the effectiveness of some antivenoms, the correct dose and frequency of administration of antivenoms to maximise their effectiveness, as well as the ability of antivenoms to cross-neutralise the effects of venom from closely related, or even unrelated, species. There is also a lack of clarity regarding the ability of antivenoms to neutralise different classes of toxins and the timeframe for this neutralisation to occur. This Special Issue of Toxins aims to provide insight into these issues as well as provide the opportunity for exploration of emerging issues in the use and/or development of antivenoms.

Prof. Dr. Wayne Hodgson
Prof. Dr. Geoff Isbister
Guest Editors

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases. Full-text available in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 20 days after submission; acceptance to publication is undertaken in 7 days (median values for papers published in this journal in 2016).

Sections: published in four topical sections.